The Study
APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline
This study watched a group of people over time and noticed that those with a certain gene (APOE4) tended to have more leaks in their brain's protective barrier, and those leaks were linked to getting worse at thinking. But it didn’t change anything on purpose—so we can’t say the leaks cause the thinking problems, just that they often happen together.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
People with the APOE4 gene have a leaky blood-brain barrier in memory areas of the brain, even before plaques or tangles form. This leak damages brain cells and leads to memory loss faster.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 558 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this leak happens early and predicts who will decline, even if they don’t yet have Alzheimer’s plaques or tangles, meaning it’s a new early warning sign.
- 2APOE4 carriers had higher BBB leakiness in the hippocampus, higher CSF sPDGFRβ (a sign of damaged brain blood vessel cells), and higher CypA/MMP9 proteins — all linked to faster memory decline over 2–4.5 years.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Nature
Year
2020
Authors
Axel Montagne, D. Nation, A. Sagare, G. Barisano, Melanie D. Sweeney, Ararat Chakhoyan, M. Pachicano, Elizabeth Joe, Amy R. Nelson, Lina M. D’Orazio, David P. Buennagel, M. Harrington, T. Benzinger, A. Fagan, J. Ringman, L. Schneider, J. Morris, E. Reiman, R. Caselli, H. Chui, J. Tcw, Yining Chen, J. Pa, P. Conti, Meng Law, A. Toga, B. Zlokovic
Related Content
Claims (6)
People with the APOE4 gene variant have higher blood-brain barrier permeability in the hippocampus and parahippocampal gyrus than those with two APOE3 copies, regardless of amyloid-beta or tau levels, and this permeability is greater in individuals with cognitive impairment.
Higher levels of soluble PDGFRβ in spinal fluid are associated with future cognitive decline in people with the APOE4 gene variant, even when amyloid-beta and tau levels are accounted for, and reflect damage to pericytes in the brain.
In people with the APOE4 gene variant, the blood-brain barrier breaks down in the hippocampus and parahippocampal gyrus before the brain shrinks or amyloid and tau proteins build up, showing this breakdown is an early and separate event in cognitive decline linked to APOE4.
In people with cognitive impairment who carry the APOE4 gene variant, a specific molecular pathway called CypA-MMP9 is active in the fluid surrounding the brain, and this activity is linked to damage to brain blood vessel support cells and leakage of the blood-brain barrier. This same pathway is not active in people with the APOE3 gene variant.
The APOE4 allele is associated with reduced clearance of amyloid-beta, increased accumulation of tau protein, damage to the blood-brain barrier, altered lipid processing in microglia, and decreased function of the glymphatic system.
People with two copies of the APOE4 gene variant have higher levels of CypA and MMP9 proteins in their cerebrospinal fluid when they have cognitive impairment, compared to those with the APOE3 variant. Human brain cells derived from stem cells with the APOE4/4 genotype also produce more of these proteins than cells with the APOE3/3 genotype.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.